Showing 4841-4850 of 10638 results for "".
Understanding Difficult-to-Treat Axial Spondyloarthritis in Real-World Practice
https://reachmd.com/programs/living-rheum/understanding-difficult-to-treat-axial-spondyloarthritis-in-real-world-practice/54369/Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
https://reachmd.com/programs/Audioabstracts/e-cigarettes-safety-lung-cancer-risk/56340/Electronic cigarettes (e-cigarettes) or vapes are often marketed as safer alternatives to conventional smoking, but their long-term respiratory health effects remain uncertain. Tune in to hear Ryan Quigley discuss emerging evidence from a systematic review examining the potential association betweenExpanding Molecular Testing in Community NSCLC Care
https://reachmd.com/programs/project-oncology/molecular-testing-community-nsclc-care/54579/Molecular testing is essential for guiding treatment in non-small cell lung cancer (NSCLC), but community practices often face significant barriers that can delay results and care. From limited biopsy samples and logistical hurdles to insurance restrictions, these challenges can slow access to next-From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
https://reachmd.com/programs/Audioabstracts/hcm-attr-cm-unexplained-hypertrophy/49052/In older patients with unexplained hypertrophy, the default diagnosis of hypertrophic cardiomyopathy (HCM) may overlook a common culprit: transthyretin amyloid cardiomyopathy (ATTR-CM). In this AudioAbstract, Dr. Hallie Blevins explores the TTRACK study, which uncovered a striking prevalence of ATTREarly Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
https://reachmd.com/programs/project-oncology/early-adulthood-weight-breast-tissue-complexity/48767/Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
https://reachmd.com/clinical-practice/oncology-hematology/amivantamab-monotherapy-or-in-combination-with-paclitaxel-in-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-origami-4-study-results/39780/In the phase 1b/2 OrigAMI-4 trial, amivantamab alone or with paclitaxel showed strong and durable responses in previously treated recurrent or metastatic HNSCC.Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
https://reachmd.com/programs/neurofrontiers/program-name/36466/New advances in Alzheimer’s treatment are reshaping how clinicians manage disease progression. Anti-amyloid monoclonal antibodies don’t reverse or cure the disease, but they can slow progression by reducing amyloid buildup and indirectly decreasing toxic tau production. Dr. Marc Haut, Director of thNicotinamide for COVID-19 Recovery: Restoring Metabolic Balance
https://reachmd.com/programs/clinicians-roundtable/nicotinamide-for-covid-19-recovery-restoring-metabolic-balance/36410/Driving Wound Care Forward: AI, Wearables, and Point-of-Care Diagnostics
https://reachmd.com/programs/clinicians-roundtable/driving-wound-care-forward-ai-wearables-and-point-of-care-diagnostics/36088/The integration of near-infrared spectroscopy, bacterial fluorescence, and AI-powered imaging is accelerating precision in wound management. Discover how sensor technology, smart bandages, and real-time data from wearables are standardizing care, reducing variability, and enabling faster clinical deOptimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
https://reachmd.com/programs/project-oncology/optimizing-nivolumab-in-nsclc-implications-for-cost-access-and-outcomes/32997/Emerging evidence suggests that combining low-dose nivolumab and chemotherapy in the neoadjuvant setting may retain immunologic efficacy while drastically lowering cost and toxicity for non-small cell lung cancer (NSCLC) patients. Additionally, this approach could help optimize trial design with dos